The effects of androgen deprivation therapy on cardiac function and heart failure: Implications for management of prostate cancer

Clinical Genitourinary Cancer

Volumn 12, Issue 6, 2014, Pages 399-407

  Edelman, Scott ^a,b   Butler, Javed ^c   Hershatter, Bruce W ^a,b   Khan, Mohammad K ^a,b  

^a Department of Radiation Oncology ^*  (United States)

^b EMORY UNIVERSITY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiandrogen; Cardiovascular system; Gonadotropin hormone releasing hormone agonist; Prostate adenocarcinoma; Testosterone

Indexed keywords

ANTIANDROGEN; DUTASTERIDE; GONADORELIN; GONADORELIN AGONIST; TESTOSTERONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RADIOTHERAPY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); GLUCOSE TOLERANCE; HEART FAILURE; HEART FUNCTION; HEART MUSCLE PERFUSION; HUMAN; MALE; METASTASIS; MUSCLE CONTRACTILITY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DRUG EFFECTS; HEART; PROSTATIC NEOPLASMS;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HEART; HEART FAILURE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84922664851     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.07.009     Document Type: Review

References (65)

1. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 2002; 360:103-8.
2. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21:3972-8.
3. Pilepich MV, Winter K, John MJ, et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50:1243-52.
4. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma e long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61:1285-90.
5. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6:841-50.
6. Laverdiere J, Abdenour N, Diaz De Bedoya L, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 2004; 171: 1137-40.
7. Edelman S, Liauw SL, Rossi PJ, et al. High-dose radiotherapy with or without androgen deprivation therapy for intermediate risk prostate cancer: Cancer control and toxicity. Int J Radiat Oncol Biol Phys 2012; 83:1473-9.
8. Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-500.
9. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25:2420-5.
10. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24:4448-56.
11. Keating NL, O'Malley J, Freedland SJ, et al. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? Eur Urol 2013; 64:159-66.
12. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99:1516-24.
13. Van Hemelrrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: Results from the populationbased PCBaSe Sweden. J Clin Oncol 2010; 28:3448-56.
14. Martin-Merino E, Johansson S, Morris T, et al. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer. Drug Saf 2011; 34:1061-77.
15. Jesperson CG, Norgaard M, Borre M, et al. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: A nationwide Danish population-based cohort study. Eur Urol 2014; 65:704-9.
16. Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. J Natl Cancer Inst 2010; 102:39-46.
17. Keating NL, O'Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer [erratum for J Natl Cancer Inst 2010; 102:39-46]. J Natl Cancer Inst 2012; 104:1518-23.
18. US Food and Drug Administration. FDA Drug Safety Communication: Update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. 2010. Available at: http://www.fda. gov/Drugs/DrugSafety/ucm229986.htm. Accessed March 6, 2014.
19. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A meta-analysis of randomized trials. JAMA 2011; 306:2359-66.
20. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 27:3452-8.
21. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009; 27:92-9.
22. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urol 2008; 54:816-24.
23. Punnen S, Cooperberg MR, Sadetsky N, et al. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 2011; 29:3510-6.
24. Roach M III, Bae K, Speight J, et al. Short term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Longterm results of RTOG 8610. J Clin Oncol 2008; 26:585-91.
25. Wilcox C, Kautto A, Steigler A, et al. Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term. Oncology 2012; 82:56-8.
26. Riihimäki M, Thomsen H, Brandt A, et al. What do prostate cancer patients die of? Oncologist 2011; 16:175-81.
27. Nguyen P, Chen M, Beckman JA, et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. Int J Radiat Oncol Biol Phys 2012; 82:1411-6.
28. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362:1192-202.
29. Mcleod DG, Iversen P, See WA, et al. Bicalutamide 150 mg plus standard care vs. standard care alone for early prostate cancer. BJU Int 2006; 97:247-54.
30. Marsh JD, Lehmann MH, Ritchie RH, et al. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation 1998; 98:256-61.
31. Golden KL, Marsh JD, Jiang Y, et al. Acute actions of testosterone on contractile function of isolated rat ventricular myocytes. Eur J Endocrinol 2005; 152:479-83.
32. Golden KL, Marsh JD, Jiang Y, et al. Gonadectomy of adult male rats reduces contractility of isolated cardiac myocytes. Am J Physiol Endocrinol Metab 2003; 285:E449-53.
33. 2+ handling and contractile function. Physiol Res 2009; 58:293-329.
34. Er F, Michels G, Gassanov N, et al. Testosterone induces cytoprotection by activating ATP-sensitive K+ channels in the cardiac mitochondrial inner membrane. Circulation 2004; 110:3100-7.
35. Zhang Y, Xing X, He B, et al. Effects of testosterone on cytokines and left ventricular remodeling following heart failure. Cell Physiol Biochem 2007; 20:847-52.
36. Dong F, Skinner DC, Wu TJ, et al. The Heart: A novel gonadotrophin-releasing hormone target. J Neuroendocrinol 2011; 23:456-63.
37. Herring MJ, Oskui PM, Hale SL, et al. Testosterone and the cardiovascular system: A comprehensive review of the basic science. J Am Heart Assoc 2013; 2: E000271.
38. Cavasin MA, Tao ZY, Yu AL, et al. Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol 2006; 290:H2043-50.
39. Vigen R, O'Donnell Baron A, et al. Association of testosterone therapy with mortality, myocardial infarction and stroke, in men with low testosterone levels. JAMA 2013; 310:1829-36.
40. Haddad RM, Kennedy CC, Caples SM, et al. Testicular and cardiovascular risk in men: A systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82:29-39.
41. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropinreleasing hormone agonist therapy for prostate cancer, differences from the classic metabolic syndrome. Cancer 2008; 112:2188-94.
42. Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100: 1690-6.
43. Kaushik M, Sontineni SP, Hunter C. Cardiovascular disease and androgens: A review. Int J Cardiol 2010; 142:8-14.
44. Malkin CJ, Jones TH, Channer KS. The effects of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail 2007; 9:44-50.
45. Nguyen CT, Aaronson A, Morrissey RP, et al. Myths and truths of growth hormone and testosterone therapy in heart failure. Expert Rev Cardiovasc Ther 2011; 9: 711-20.
46. Feldman HA, Johannes CB, Mckinlay JB, et al. Low dehydroepiandrosterone sulfate and heart disease in middle-aged men: Cross-sectional results from the Massachusetts Male Aging Study. Ann Epidemiol 1998; 8:217-28.
47. Chaggar PS, Malkin CJ, Shaw SM, et al. Neuroendocrine effects on the heart and targets for therapeuticmanipulation in heart failure. Cardiovasc Ther 2009; 27:187-93.
48. Guder G, Frantz S, Bauersachs J, et al. Low circulating androgens and mortality risk in heart failure. Heart 2010; 96:504-9.
49. Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure prevalence and detrimental impact on survival. Circulation 2006; 114:1829-37.
50. Malkin C, Pugh P, West J, et al. Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. Eur Heart J 2006; 27:57-64.
51. Caminiti G, VolterraniM, IellamoR, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure: A double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54:919-27.
52. Pugh PJ, Jones RD, West JN, et al. Testosterone treatment for men with chronic heart failure. Heart 2004; 90:446-7.
53. Tomoda H. Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am J Cardiol 1999; 83:123-5, A129.
54. Chung T, Kelleher S, Liu PY, et al. Effects of testosterone and nandrolone on cardiac function: A randomized, placebo-controlled study. Clin Endocrinol 2007; 66:235-45.
55. Lester-Coll NH, Goldhaber SZ, Sher DJ, et al. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy, a decision analysis. Cancer 2013; 119:1808-15.
56. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU Guidelines on prostate cancer. Part I: Screening, diagnosis and local treatment with curative intenteupdate 2013. Eur Urol 2014; 65:124-37.
57. Horwitz EM, Bae K, Hanks GE. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-504.
58. D'Amico AV, Manola J, Loffredo M, et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer, a randomized controlled trial. JAMA 2004; 292: 821-7.
59. Bolla M, De Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27.
60. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing and castration-resistant prostate cancer. Eur Urol 2014; 65:467-79.
61. Garcia-Albeniz X, Chan JM, Paciorek AT, et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. ASCO Annual Meeting 2014; abstract 5003.
62. Crook JM, O'Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367:895-903.
63. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing and castration-resistant prostate cancer. Eur Urol 2011; 59:572-83.
64. Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368:1314-25.
65. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. Circulation 2010; 121: 833-40.